PLOD2 hydroxylates telopeptidyl lysine residues on collagen, subsequently increasing the level of hydroxylysine aldehyde–derived collagen cross-links (HLCCs) and lowering levels of lysine aldehyde–derived cross-links in lung cancer tissue (Chen et al., 2015). The gene discussed is PLOD2; the disease is lung carcinoma.